晚孕期及足月胎儿室上性心律失常的治疗而非分娩
该回顾性病例系列纳入2012至2022年间六家机构中≥35周妊娠、持续胎儿室上性心律失常(SVA)并接受经胎盘治疗的37例胎儿,中位孕35.7周。宫内治疗使35例(95%)恢复窦性心律,中位2天;57%出生后SVA复发,多数经阴道分娩。
要点
- ≥35周持续胎儿SVA经胎盘治疗恢复窦性心律达95%,包括4例水肿胎儿中的3例。
- 抗心律失常药包括氟卡尼、地高辛、索他洛尔及联合治疗,转律中位时间2天。
- 57%病例出生后SVA复发,62%经阴道分娩,38%剖宫产。
核心结论
- 对≥35周近足月及足月SVA胎儿进行宫内治疗高度成功,即使存在水肿,多数病例接近足月经阴道分娩,从而避免不必要的剖宫产。
研究设计与样本
- 回顾性病例系列,纳入2012至2022年间六家机构中≥35周妊娠、持续SVA并接受经胎盘治疗的37例胎儿。
主要发现
- 37例胎儿中位孕35.7周(范围35.0-39.7),短VA心动过速20例、长VA心动过速7例、心房扑动10例,4例(11%)水肿。
- 宫内治疗使35例(95%)恢复窦性心律,中位2天(范围1-17天),包括4例水肿胎儿中的3例。
- 抗心律失常药为氟卡尼11例、地高辛7例、索他洛尔11例、联合治疗8例。
- 新生儿36-41周活产,经阴道分娩23/37(62%),剖宫产14/37(38%);剖宫产指征为胎儿SVA 2例、房性早搏或窦性心动过缓3例、产科原因9例(分娩时均为窦性心律)。
- 21例(57%)出生后因SVA复发接受治疗。
临床怎么用
- 原文结论认为对≥35周近足月及足月SVA胎儿进行宫内治疗高度成功,即使存在水肿,多数病例接近足月经阴道分娩,避免不必要的剖宫产。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: While in-utero treatment of sustained fetal supraventricular arrhythmia (SVA) is standard practice in the previable and preterm fetus, data are limited on best practice for late preterm (34 + 0 to 36 + 6 weeks), early term (37 + 0 to 38 + 6 weeks) and term (> 39 weeks) fetuses with SVA. We reviewed the delivery and postnatal outcomes of fetuses at ≥ 35 weeks of gestation undergoing treatment rather than immediate delivery. METHODS: This was a retrospective case series of fetuses presenting at ≥ 35 weeks of gestation with sustained SVA and treated transplacentally at six institutions between 2012 and 2022. Data were collected on gestational age at presentation and delivery, SVA diagnosis (short ventriculoatrial (VA) tachycardia, long VA tachycardia or atrial flutter), type of antiarrhythmic medication used, interval between treatment and conversion to sinus rhythm and postnatal SVA recurrence. RESULTS: Overall, 37 fetuses presented at a median gestational age of 35.7 (range, 35.0-39.7) weeks with short VA tachycardia (n = 20), long VA tachycardia (n = 7) or atrial flutter (n = 10). Four (11%) fetuses were hydropic. In-utero treatment led to restoration of sinus rhythm in 35 (95%) fetuses at a median of 2 (range, 1-17) days; this included three of the four fetuses with hydrops. Antiarrhythmic medications included flecainide (n = 11), digoxin (n = 7), sotalol (n = 11) and dual therapy (n = 8). Neonates were liveborn at 36-41 weeks via spontaneous vaginal delivery (23/37 (62%)) or Cesarean delivery (14/37 (38%)). Cesarean delivery was indicated for fetal SVA in two fetuses, atrial ectopy or sinus bradycardia in three fetuses and obstetric reasons in nine fetuses that were in sinus rhythm at the time of delivery. Twenty-one (57%) cases were treated for recurrent SVA after birth. CONCLUSION: In-utero treatment of the near term and term (≥ 35-week) SVA fetus is highly successful even in the presence of hydrops, with the majority of cases delivered vaginally closer to term, thereby avoiding unnecessary Cesarean section. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Holmes S, Hornberger LK, Jaeggi E, et al. Treatment, not delivery, of the late preterm and term fetus with supraventricular arrhythmia. Ultrasound Obstet Gynecol. 2023. PMID: 37128167. doi:10.1002/uog.26239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。